Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
28 November 2022 | Story Rulanzen Martin | Photo Anja Aucamp
Prof Melanie Walker
Prof Melanie Walker is one of two NRF A1-rated scholars at the UFS.

The Higher Education and Human Development (HEHD) research group under the leadership of Prof Melanie Walker has grown to become a pocket of academic excellence and innovation at the UFS. “The group’s research positions universities (if ‘reimagined’) as potentially powerful sites for achieving human development by challenging the status quo and entrenched interests and inequalities,” Prof Walker notes. 

HEHD researchers draw substantially on the capability approach, which offers a contribution to higher education in South Africa, primarily because it derives from a normative framework that places human flourishing as its primary goal, chiming with the country’s transformation goals.

Prof Walker is an internationally acclaimed researcher and academic and one of three A-rated National Research Foundation (NRF) scholars at the UFS. In 2021, she was elected as the first president of the international Human Development and Capability Association (HDCA) from the Global South. Back then, Prof Walker said the UFS already had a strong research presence within the HDCA, and her group was known for its work in African higher education. The HDCA brings together academics who generate ideas and research on human development.

The research group, which was founded by Prof Walker, is an embodiment of the quality and of the impact elements of the institutional narrative of the UFS. The HEHD is now happily based in the Centre for Development Support within the UFS Faculty of Economic and Management Sciences.

Top-tier research outputs from HEHD

The outputs of the HEHD research group have a far-reaching impact, given the nature of its national and international affiliated researchers, students, and collaborators. Members of the group have published 19 peer-reviewed books since 2013, and since 2016, the HEHD has graduated 20 PhDs whose research focuses on diverse aspects of higher education and capabilities across the sub- Saharan region. A range of international examiners in the USA, the UK and Europe attest to the quality of the HEHD’s doctoral graduates.

“I am immensely proud of the quality of the research and collective ethos of our graduate students and our researchers and, as importantly, the substantive focus on human development and social justice in and through higher education in Africa,” Prof Walker says. “As Professor Tristan McCowan and others have noted, this group is quite unique internationally,” she continues.

Projects and research collaborations

The numerous institutional and national and international research collaborations are also testament to the interdisciplinarity of Prof Walker’s academic approach. Various recent and current projects attest to this, for example, the recently completed Miratho project on inclusive higher education learning outcomes for low-income rural youth with Birmingham and Nottingham.

Some of the the book titles that have been published by HEHD members past and present, on display on the wall in the Benito Khotseng Building on the Bloemfontein Campus. (Photo: Anja Aucamp) 


A further current example is the project under the Transforming Education for Sustainable Futures (TESF) with Bristol and Rhodes led by Dr Mikateko Mathebula, and a new edited book underway with Alejandra Boni and Diana Velasco (Spain) on higher education and reparative futures.

 
Furthermore, national collaborations such as the project with colleagues in the Centre for Development Support at the UFS and the University of Pretoria, which will be investigating the sustainable (ecologically and socially), developmental South African university and justice facing university futures from a variety of stakeholder 
perspectives.

This research project is informed by the 17 Sustainable Development Goals, because achieving them cannot be done without the contributions of higher education institutions.

It is thus evident that under the leadership of Prof Walker, the HEHD research group is now established as one of the finest research groups at the UFS and contributes actively to the research and academic excellence at the university.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept